(Reuters) -Pfizer said on Friday it has received an early clearance from the U.S. Federal Trade Commission for its proposed acquisition of Metsera, removing a key regulatory hurdle for the deal valued at up to $7.3 billion. The FTC granted early termination of the waiting period required under the Hart-Scott-Rodino Act, which governs antitrust reviews of large mergers. The waiting period was originally set to expire on November 7. The clearance means Pfizer can move ahead with its proposed purchase of Metsera without further antitrust review from U.S. regulators. Shares of Pfizer closed about 1.5% higher on Friday. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Rich McKay (Reuters) -In a testament to Kim Kardashian's power to grab the spotlight,…
By Hanna Rantala LUCCA, Italy (Reuters) -Fans can expect more action and plenty of emotion…
(Reuters) -U.S. President Donald Trump will sit down with CBS anchor Norah O'Donnell for an interview…
(Reuters) -The U.S. Department of Energy on Friday announced that it would make $100 million…
By Saeed Azhar and Pritam Biswas (Reuters) -Bank of America promoted Denis Manelski and Soofian…
By Akash Sriram (Reuters) -A momentous week in the technology sector made it clear there…